Threshold values for the 1-way sensitivity analyses from the adverse- and intermediate-risk Markov models
| Health state probability or utility . | Adverse-risk favors IC . | Intermediate-risk favors AZ . |
|---|---|---|
| Relapse with AZ and SCT | — | — |
| Death after relapse with AZ and SCT | — | — |
| Death within the first year of AZ and SCT | >0.44 | <0.05 |
| SCT after induction with AZ | <0.11 | >0.5 |
| Relapse with AZ and no SCT | — | — |
| Death after relapse with AZ and no SCT | — | — |
| Death within the first year of AZ and no SCT | — | <0.05 |
| Composite CR with AZ after primary refractory disease | — | >0.8 |
| Relapse with IC and SCT | — | >0.89 |
| Death after relapse with IC and SCT | — | — |
| Death within the first year of IC and SCT | <0.01 | >0.39 |
| SCT after induction with IC | — | <0.07 |
| Relapse with IC and no SCT | — | >0.82 |
| Death after relapse with IC and no SCT | — | — |
| Death within the first year with IC and no SCT | <0.02 | — |
| Composite CR with IC after primary refractory disease | — | — |
| Health utility of DFS if treated with AZ | <0.56 | >0.98 |
| Health utility of relapse if treated with AZ | — | — |
| Health utility of DFS if treated with IC | — | <0.68 |
| Health utility of relapse if treated with IC | — | — |
| Health state probability or utility . | Adverse-risk favors IC . | Intermediate-risk favors AZ . |
|---|---|---|
| Relapse with AZ and SCT | — | — |
| Death after relapse with AZ and SCT | — | — |
| Death within the first year of AZ and SCT | >0.44 | <0.05 |
| SCT after induction with AZ | <0.11 | >0.5 |
| Relapse with AZ and no SCT | — | — |
| Death after relapse with AZ and no SCT | — | — |
| Death within the first year of AZ and no SCT | — | <0.05 |
| Composite CR with AZ after primary refractory disease | — | >0.8 |
| Relapse with IC and SCT | — | >0.89 |
| Death after relapse with IC and SCT | — | — |
| Death within the first year of IC and SCT | <0.01 | >0.39 |
| SCT after induction with IC | — | <0.07 |
| Relapse with IC and no SCT | — | >0.82 |
| Death after relapse with IC and no SCT | — | — |
| Death within the first year with IC and no SCT | <0.02 | — |
| Composite CR with IC after primary refractory disease | — | — |
| Health utility of DFS if treated with AZ | <0.56 | >0.98 |
| Health utility of relapse if treated with AZ | — | — |
| Health utility of DFS if treated with IC | — | <0.68 |
| Health utility of relapse if treated with IC | — | — |
AZ, azacitidine and venetoclax